- Home
- CAAP vs RYTM Comparison
CAAP vs RYTM Comparison
Compare CAAP & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAAP
- RYTM
- Stock Information
- Founded
- CAAP 1998
- RYTM 2008
- Country
- CAAP Luxembourg
- RYTM United States
- Employees
- CAAP N/A
- RYTM N/A
- Industry
- CAAP Aerospace
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- CAAP Consumer Discretionary
- RYTM Health Care
- Exchange
- CAAP Nasdaq
- RYTM Nasdaq
- Market Cap
- CAAP 3.0B
- RYTM 3.1B
- IPO Year
- CAAP 2018
- RYTM 2017
- Fundamental
- Price
- CAAP $19.79
- RYTM $56.50
- Analyst Decision
- CAAP Strong Buy
- RYTM Strong Buy
- Analyst Count
- CAAP 1
- RYTM 10
- Target Price
- CAAP $21.50
- RYTM $66.90
- AVG Volume (30 Days)
- CAAP 140.3K
- RYTM 549.1K
- Earning Date
- CAAP 11-20-2024
- RYTM 02-20-2025
- Dividend Yield
- CAAP N/A
- RYTM N/A
- EPS Growth
- CAAP 115.99
- RYTM N/A
- EPS
- CAAP 2.09
- RYTM N/A
- Revenue
- CAAP $1,496,122,000.00
- RYTM $112,530,000.00
- Revenue This Year
- CAAP $19.21
- RYTM $63.77
- Revenue Next Year
- CAAP $14.26
- RYTM $44.91
- P/E Ratio
- CAAP $8.78
- RYTM N/A
- Revenue Growth
- CAAP N/A
- RYTM 81.55
- 52 Week Low
- CAAP $13.74
- RYTM $35.17
- 52 Week High
- CAAP $20.79
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- CAAP 56.22
- RYTM 52.43
- Support Level
- CAAP $18.31
- RYTM $52.71
- Resistance Level
- CAAP $19.98
- RYTM $60.12
- Average True Range (ATR)
- CAAP 0.69
- RYTM 2.11
- MACD
- CAAP 0.05
- RYTM -0.00
- Stochastic Oscillator
- CAAP 86.58
- RYTM 58.93
About CAAP Corporacion America Airports SA
Corporacion America Airports SA acquires, develops and operates airport concessions. Its operating segments are geographically divided into Argentina, Italy, Brazil, Uruguay, Ecuador and Armenia. The company generates a majority of its revenue from the Argentina segment. The firm's revenue is categorized into Aeronautical Revenue, Non-Aeronautical Revenue, Commercial Revenue, Construction Service Revenue, and Other Revenue.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.